ALLMedicine™ Acute Myeloid Leukemia Center
Research & Reviews 8,726 results
https://doi.org/10.1007/s00520-021-06339-x 10.1093/annonc/mdv296 10.1111/j.1751-553X.2007.00931.x 10.1016/j.idc.2017.05.007 10.1086/671737 10.3109/10428190309178770 10.5301/jva.5000216 10.3109/10428194.2012.742520 10.1016/j.jpedsurg.2007.02.008 10.1007/s00277-016-2798-4 10.3109/10428194.2011.639879 10.3109/10428190109057936 10.1182/blood-2016-03-643544 10.1093/cid/cir257 10.1093/cid/ciu670 10.1200/JCO.2012.45.5733 10.1016/j.clml.2018.12.008 10.1007/s00520-003-0558-1 10.1007/s00520-008-0449-6
Supportive Care in Cancer : Official Journal of the Multi... McKeown C, Ricciuti A et. al.
Sep 26th, 2021 - Central venous catheters (CVCs) are widely used in acute myeloid leukemia (AML) patients. Complications associated with CVCs are frequently encountered and contribute to morbidity and mortality. Prospective studies investigating and comparing comp...
https://doi.org/10.1002/cam4.4284
Cancer Medicine; Zhang LY, Jin Y et. al.
Sep 26th, 2021 - The role of B7-H3 in acute myeloid leukemia (AML) is not fully understood. Two previous studies investigating its expression and significances in AML are partially different. In this study, we aimed to systematically characterize the genomic and i...
https://doi.org/10.1038/s41408-021-00553-w 10.1182/blood-2010-10-265603 10.1182/asheducation-2015.1.596 10.1182/blood-2015-07-604546 10.1007/s12185-014-1657-0 10.1038/s41409-018-0301-7 10.1007/s00277-020-04051-0 10.1038/s41409-021-01247-4 10.1182/blood-2010-09-309229 10.1016/j.clml.2012.07.004 10.1038/leu.2014.332 10.1038/bmt.2015.349 10.1016/j.bbmt.2017.05.008 10.1007/s12185-019-02759-y 10.1038/bmt.2016.18 10.1038/s41409-021-01227-8 10.7326/0003-4819-120-8-199404150-00004 10.1182/blood-2004-02-0508 10.3324/haematol.11277 10.1007/s12185-015-1894-x 10.1007/s12185-015-1907-9 10.1056/NEJM200106143442402 10.1182/blood-2005-05-2004 10.1080/10428194.2017.1357173 10.1002/(SICI)1097-0258(19981015)17:19<2265::AID-SIM918>3.0.CO;2-B 10.1080/00273171.2011.568786 10.1038/bmt.2012.244 10.1200/JCO.2005.09.020 10.1007/s12185-010-0581-1 10.1056/NEJMoa1203517 10.1016/j.bbmt.2015.12.027 10.1016/j.bbmt.2019.09.036 10.1038/s41409-020-0826-4 10.1038/bmt.2013.147 10.1182/blood-2013-12-542464 10.3324/haematol.2018.200121 10.1200/JCO.2007.15.9814 10.1038/bmt.2012.139 10.1111/bjh.12358 10.1182/blood-2013-06-506725 10.1038/bmt.2015.170 10.1111/bjh.13912 10.1002/ajmg.c.30212
Blood Cancer Journal; Kurosawa S, Mizuno S et. al.
Sep 26th, 2021 - The present study evaluated outcomes and prognostic factors in adult patients with acute myeloid leukemia (AML) after syngeneic hematopoietic stem cell transplantation (HSCT). Among patients in first complete remission (CR1), outcomes of syngeneic...
https://doi.org/10.1038/s41588-021-00925-9 10.1146/annurev.genom.7.080505.115623 10.1016/j.tig.2012.03.006 10.1038/nrg3207 10.1038/s41576-019-0128-0 10.1038/nature25022 10.1016/j.devcel.2015.12.014 10.1016/j.cell.2008.01.025 10.1038/nri2991 10.1056/NEJMoa1301689 10.1182/blood-2015-07-604496 10.1056/NEJMoa1516192 10.1056/NEJMra1406184 10.1038/nrc989 10.1016/j.ccr.2007.08.031 10.1038/ng.796 10.1038/leu.2013.77 10.1038/nmeth.2688 10.1038/ng.3286 10.1038/s41588-018-0270-1 10.1038/nrg3017 10.1182/blood-2010-10-313031 10.1016/j.ccr.2014.02.008 10.1016/j.celrep.2017.05.003 10.1016/j.molcel.2013.01.038 10.1126/science.1256271 10.1016/j.molcel.2010.05.004 10.1126/science.1181369 10.1046/j.1365-2141.2003.04640.x 10.7554/eLife.21926 10.1038/ng.3935 10.1016/j.celrep.2020.107532 10.1038/nbt.3192 10.1182/blood.V98.10.2958 10.1128/MCB.25.7.2832-2845.2005 10.1038/ng1679 10.1038/nm.3936 10.1101/gr.121145.111 10.1016/j.stem.2015.09.017 10.1038/leu.2013.338 10.1016/j.celrep.2016.07.032 10.1038/s41388-018-0150-2 10.1182/blood-2017-01-760595 10.1002/jlb.63.2.139 10.1016/j.tcb.2018.04.009 10.1111/j.1600-065X.2010.00955.x 10.1111/imm.12535 10.1016/j.celrep.2015.06.069 10.1021/bi101835j 10.1371/journal.pgen.1000889 10.1091/mbc.e10-06-0508 10.1038/cr.2018.1 10.1016/j.celrep.2016.09.079 10.1016/j.cell.2017.01.013 10.1016/j.stem.2019.07.001 10.1182/blood-2005-02-0717 10.1182/blood-2009-03-212225 10.1182/blood-2010-11-317909 10.1182/blood-2002-04-1288 10.1038/s41467-019-10652-9 10.1182/blood-2017-09-807024 10.1038/s41588-018-0114-z 10.1007/s002770050366 10.1128/MCB.00936-06 10.1182/blood-2011-03-341081 10.1038/leu.2013.384 10.1016/j.ydbio.2017.02.009 10.1126/science.1207194 10.1093/bioinformatics/bts635 10.1093/bioinformatics/btp616 10.1186/s13059-016-0881-8 10.1186/s13059-014-0550-8 10.1371/journal.pcbi.1003326 10.1186/gb-2009-10-3-r25 10.1038/nature10730 10.1093/nar/gkw257 10.12688/f1000research.7334.1 10.1186/s13059-016-0992-2
Nature Genetics; Yun H, Narayan N et. al.
Sep 25th, 2021 - Altered transcription is a cardinal feature of acute myeloid leukemia (AML); however, exactly how mutations synergize to remodel the epigenetic landscape and rewire three-dimensional DNA topology is unknown. Here, we apply an integrated genomic ap...
https://doi.org/10.1182/bloodadvances.2021005236
Blood Advances; Angenendt L, Wöste M et. al.
Sep 25th, 2021 - We have recently identified the G protein-coupled neuropeptide receptor Calcitonin receptor-like (CALCRL) as an independent prognostic biomarker and a therapeutic target in more than 1500 adult patients with acute myeloid leukemia (AML). Here, we ...
Guidelines 10 results
https://doi.org/10.1016/j.bbmt.2020.09.020
Biology of Blood and Marrow Transplantation : Journal of ... Dholaria B, Savani BN et. al.
Sep 24th, 2020 - The role of hematopoietic cell transplantation (HCT) in the management of newly diagnosed adult acute myeloid leukemia (AML) is reviewed and critically evaluated in this evidence-based review. An AML expert panel, consisting of both transplant and...
https://doi.org/10.6004/jnccn.2017.0157
Journal of the National Comprehensive Cancer Network : JN... Mesa RA, Jamieson C et. al.
Oct 7th, 2017 - Myeloproliferative neoplasms (MPNs) are a group of heterogeneous disorders of the hematopoietic system that include myelofibrosis (MF), polycythemia vera (PV), and essential thrombocythemia (ET). PV and ET are characterized by significant thromboh...
https://doi.org/10.6004/jnccn.2017.0116
Journal of the National Comprehensive Cancer Network : JN... O'Donnell MR, Tallman MS et. al.
Jul 9th, 2017 - Acute myeloid leukemia (AML) is the most common form of acute leukemia among adults and accounts for the largest number of annual deaths due to leukemias in the United States. This portion of the NCCN Guidelines for AML focuses on management and p...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4161234
Journal of the National Comprehensive Cancer Network : JN... O'Donnell MR, Tallman MS et. al.
Sep 14th, 2013 - These NCCN Guidelines Insights summarize several key updates to the NCCN Guidelines for Acute Myeloid Leukemia and discuss the clinical evidence that support the recommendations. The updates described in this article focus on the acute promyelocyt...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4000017
Journal of the National Comprehensive Cancer Network : JN... Greenberg PL, Attar E et. al.
Jul 13th, 2013 - The myelodysplastic syndromes (MDS) represent a heterogeneous group of clonal hematopoietic disorders characterized by cytopenias, dysplasia in one or more myeloid lineages, and the potential for development of acute myeloid leukemia. These disord...
Drugs 28 results see all →
News 769 results
https://www.medscape.com/viewarticle/955064
Jul 21st, 2021 - NEW YORK (Reuters Health) - The combination of ficlatuzumab plus chemotherapy showed considerable early promise in relapsed/refractory acute myeloid leukemia (AML) in a small phase-1 study. "The high rate of complete remissions was surprising to u...
https://www.medscape.com/viewarticle/953734
Jun 25th, 2021 - Hypomethylating agents are generally considered to be agents of choice for older adults with acute myeloid leukemia who cannot tolerate the rigors of more intensive therapies, but HMAs also can serve as a bridge to transplant for children and youn...
https://www.medscape.com/viewarticle/953436
Jun 21st, 2021 - Among older patients with acute myeloid leukemia (AML), survival is significantly better when they undergo reduced-intensity condition (RIC) before receiving an allogeneic hematopoietic cell transplant (HCT) at first remission. This improvement in...
https://reference.medscape.com/viewarticle/950473
May 12th, 2021 - Myelodysplastic syndrome (MDS) is a group of related disorders that arise as the result of distorted hematopoietic stem cell function, inflammatory and innate immune deregulation, and multiple genomic events. These molecular alterations increase t...
https://www.medscape.com/viewarticle/947261
Mar 11th, 2021 - Almost 20 years after the human genome was first mapped, whole-genome sequencing might finally be ready to enter routine cancer care. Researchers at Washington University in St. Louis, St. Louis, Missouri, are commercializing an automated sequenci...
